Last reviewed · How we verify
SSD8432 dose 10~12 and ritonavir — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
SSD8432 dose 10~12 and ritonavir (SSD8432 dose 10~12 and ritonavir) — Jiangsu Simcere Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SSD8432 dose 10~12 and ritonavir TARGET | SSD8432 dose 10~12 and ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SSD8432 dose 10~12 and ritonavir CI watch — RSS
- SSD8432 dose 10~12 and ritonavir CI watch — Atom
- SSD8432 dose 10~12 and ritonavir CI watch — JSON
- SSD8432 dose 10~12 and ritonavir alone — RSS
Cite this brief
Drug Landscape (2026). SSD8432 dose 10~12 and ritonavir — Competitive Intelligence Brief. https://druglandscape.com/ci/ssd8432-dose-10-12-and-ritonavir. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab